Antibody-drug conjugates (ADCs) are an emerging class of anticancer agents that combine targeting antibodies with potent cytotoxic agents. Their molecular configuration allows for increased therapeutic efficacy and reduced adverse-effect profiles compared to monoclonal antibodies or cytotoxic chemotherapy alone. ADCs cause off-target toxicities through several mechanisms, including premature deconjugation of the cytotoxic agent in the serum and the presence of the targeted antigen on normal tissues. Given cutaneous adverse events comprise 31.3% of all-grade adverse events in clinical trials involving ADCs, dermatologists are increasingly called upon to manage the cutaneous toxicities caused by these drugs. In this review, we summarize known cutaneous toxicities of the ADCs that have been approved for use by the US Food and Drug Administration to date. Dermatologists can play a key role in recognizing cutaneous reactions associated with ADCs, contributing to guidelines for their management, and aiding during clinical trials to generate detailed morphologic and histopathologic descriptions of cutaneous toxicities caused by ADCs.

中文翻译：

---

抗体-药物偶联物的皮肤不良反应综述


抗体-药物偶联物 （ADC） 是一类新兴的抗癌药物，它将靶向抗体与强效细胞毒性药物相结合。与单独的单克隆抗体或细胞毒性化疗相比，它们的分子结构可以提高治疗效果并减少不良反应。ADC 通过多种机制引起脱靶毒性，包括血清中细胞毒剂的过早解离以及正常组织上存在靶抗原。鉴于皮肤不良事件占涉及 ADC 的临床试验中所有级别不良事件的 31.3%，皮肤科医生越来越多地被要求管理这些药物引起的皮肤毒性。在本综述中，我们总结了迄今为止已被美国食品和药物管理局批准使用的 ADC 的已知皮肤毒性。皮肤科医生可以在识别与 ADC 相关的皮肤反应方面发挥关键作用，为其管理指南做出贡献，并在临床试验期间协助生成 ADC 引起的皮肤毒性的详细形态学和组织病理学描述。